Propagation of RML Prions in Mice Expressing PrP Devoid of GPI Anchor Leads to Formation of a Novel, Stable Prion Strain

Sukhvir Paul Mahal1, Joseph Jablonski1, Irena Suponitsky-Kroyter1,2, Anja Maria Oelschlegel1, Maria Eugenia Herva1,2, Michael Oldstone2, Charles Weissmann1*

1 Department of Infectology, Scripps Florida, Jupiter, Florida, United States of America, 2 Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America

Abstract

PrPSc, a host protein which in prion-infected animals is converted to PrPSc, is linked to the cell membrane by a GPI anchor. Mice expressing PrPSc without GPI anchor (tgGPI- mice), are susceptible to prion infection but accumulate anchorless PrPSc extra- rather than intracellularly. We investigated whether tgGPI- mice could faithfully propagate prion strains despite the deviant structure and location of anchorless PrPSc. We found that RML and ME7, but not 22L prions propagated in tgGPI- brain developed novel cell tropisms, as determined by the Cell Panel Assay (CPA). Surprisingly, the levels of protease-resistant PrPSc (PrPres) in RML- or ME7-infected tgGPI- brain were 25–50 times higher than in wild-type brain. When returned to wild-type brain, ME7 prions recovered their original properties, however RML prions had given rise to a novel prion strain, designated SFL, which remained unchanged even after three passages in wild-type mice. Because both RML PrPSc and SFL PrPSc are stably propagated in wild-type mice we propose that the two conformations are separated by a high activation energy barrier which is abrogated in tgGPI- mice.

Introduction

Prions, the causative agents of transmissible spongiform encephalopathies, contain as their main component PrPSc, a multimeric conformer of the ubiquitous host protein PrPC. PrPC can carry one or two N-linked glycans, whose structure is highly variable [1–3], or remain unglycosylated; moreover the glycosylation state varies in different tissues and cell lines, and even in different brain regions [4–6]. Most PrPC is attached to the outer surface of the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor [7], but transmembrane forms have been identified [8,9]. In prion-infected cells PrPC is converted to PrPSc at the membrane [10] and within the endosomal/lysosomal compartment [11], and accumulates mainly in intracellular compartments [12,13]. While PrPSc is readily cleaved off the cell surface by PIPLC [7], PrPSc is not, even though it retains its GPI anchor [14]. PrPSc presents as a partially protease K (PK)-resistant form, designated rPrPSc or PrPres, or as a PK-sensitive entity, sPrPSc or PrPScw [15–17].

Mouse prions occur in the form of a wide variety of strains, which have the same PrP sequence but differ in their incubation time in various mouse lines and in the pattern of lesions they cause in brain [18]. It is believed that strain-ness is encoded by the conformation of PrPSc and in many instances there are differences in the physicochemical properties of the cognate PrPSc [19–24]. Interestingly, different prion strains populate distinct regions of the brain [25–27] and are selective in regard to the cultured cell lines they can chronically infect [28–33]. This raises the unanswered question as to which cellular property underlies prion strain tropism.

The seeding or nucleation model for prion propagation [34–36] predicates that PrPSc monomers add to PrPSc and in doing so assume the conformation of its subunits, thus allowing faithful propagation of strains. A prerequisite for chronic infection is that PrPSc monomers with a conformation allowing efficient accretion be present at a concentration sufficient to allow synthesis of PrPSc at a rate higher than that of its depletion [37–39]. PrPSc is conformationally very flexible [40–42] but certain conformations may be more frequent in some cell types but less so or absent in others, which could account for the tropism of prion strains. This proposal begs the question as to why certain conformations would be favored in some cells but not in others. One possibility is that PrPSc conformation is modulated by the association of PrPSc with a cell-specific component, RNA and phospholipids being two possibilities among several [43,44]. PrP has a strong binding affinity for polyamines, in particular RNA and homoribopolynucleotides [45,46]. Binding of RNA causes conformational changes of PrP [47,48] and in vitro conversion of purified PrPSc or...
The agent causing transmissible spongiform encephalopathies, the prion, consists mainly if not entirely of PrPSc, an aggregated conformational variant of PrP. PrPSc is a host-specified glycoprotein which is attached to the outer surface of the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. PrPSc is thought to propagate by seeded conversion, in which PrPSc accretes to an aggregate of PrPSc and thereby assumes its conformation. Prions occur as distinct strains, which have the same PrP sequence but different PrPSc conformations. Many strains are very stable but some can “mutate”, especially after transient propagation in another animal species. Here “mutation” is attributed to a conformational change of the underlying PrPSc protein rather than a change in the nucleotide sequence of a gene. In transgenic mice that express anchorless PrP, conversion to PrPSc occurs extracellularly rather than in a cell-associated compartment. Surprisingly, RML, a very stable prion strain, when propagated in tgGPI mice and then returned to wild-type mice, was recovered as a novel strain, designated SFL, which was stable over many transmissions. Thus, faithful strain propagation was abrogated either as a consequence of the modified PrP or because of a different replication mode in the extracellular compartment of tgGPI mice.

recombinant PrP to infectious PrPSc by Protein Misfolding Cyclic Amplification (PMCA) requires the presence of a polyanion and/or phospholipid [44,49–51]. Another possibility is that the highly variable glycosylation of PrPSc observed in different cells and tissues [52] might affect its susceptibility to conversion to PrPSc, because of an effect on its conformation [53] or its interactions with putative auxiliary host proteins such as the conjectured protein X [54]. Distinct PrPSc glycoforms promote PMCA-mediated prion formation in a species-specific manner [55]. There have been many attempts to explore the role of glycans in the fidelity of strain propagation, in particular by generating amino acid replacements at the glycosylation sites [53,56–58].

Some years ago Chesebro et al. generated transgenic mice lacking the PrP GPI signal sequence on a PrP null background (tgGPI mice) [60]. In mice hemizygous for the transgenes, PrP devoid of the GPI anchor (GPI−PrP) was expressed at about one quarter the level of PrP in wild-type controls, was largely unglycosylated and absent from the plasma membrane. Nonetheless, these mice, inoculated with RML or 22L prions accumulated high levels of infectivity and PK-resistant PrP in the form of extracellular amyloid plaques in their brains, but exhibited no striking clinical signs up to 600 and 400 days post infection (dpi), respectively. GPI−PrP to GPI−PrPSc conversion is believed to occur extracellularly [11,60–62]. Mice homozygous for the transgenes expressing GPI−PrP at a twofold higher level than their hemizygous counterparts developed neurological signs from 300 to 480 dpi [63]. Cultured cells expressing GPI−PrP secreted the bulk of the anchorless PrP into the medium, none was found at the cell surface but some was associated with membrane fractions [64]. Cells expressing epitope-tagged GPI−PrP exposed to 22L prions did not become chronically infected, however during the acute infection phase, tagged PrP was transiently formed [61,65].

To determine whether prions formed from PrPSc that had the same sequence but different post-translational modifications would retain their strain characteristics, we inoculated tgGPI mice with various prion strains or isolates and determined the cell tropism of the resulting isolates by the Cell Panel Assay (CPA) [53]. We found that the CPA properties of 22L prions remained unchanged, whereas those of RML, 139A, 79A and ME7 prions became distinctly different when propagated in tgGPI mice. RML, 139A and 79A prions are derived from drowsy goat scrapie and are related [66,67] while ME7 and 22L are distinct and unrelated strains derived from sheep scrapie [68]. Because the changes in properties could have been due to the absence of the GPI anchor and/or to diminished glycosylation, RML and ME7 prions propagated in GPI− mice were transferred to wild-type mice and their properties were again assessed. As judged by the CPA, ME7 prions recovered their original properties after one passage, showing that their adaptation to the GPI− environment was readily reversible. RML-derived prions, however, did not recover their original cell tropism, even after three cycles of propagation in wild-type mice, and therefore constituted a novel, stable strain, which we designated “SFL” (“Scripps Florida Laboratory”). Because both RML and SFL prions were stably propagated in wild-type mice, we propose that the two conformations are separated by a high activation energy barrier which is abrogated in tgGPI− mice, either because of the different structure or reduced expression level of the hypoglycosylated GPI-less PrPSc, or because of a different replication mode in the extracellular space.

Inoculation of tgGPI− mice with various prion strains

TgGPI− mice express a PrP construct in which a nonsense codon replaces that for serine233, the residue to which the GPI moiety is added in wild-type PrP; thus, the polypeptide chains are identical in the transgenic and wild-type mice [60].

TgGPI− mice [60] (GPI− for short) and C57BL/6 wild-type mice (C57 for short) were inoculated with the mouse-adapted scrapie prion strains 22L, RML, 79A, 139A and ME7 to give GPI [22L], GPI [RML], GPI [79A], GPI [139A] and GPI [ME7] prions (Table S1). GPI [ME7] and GPI [RML] brain homogenate was injected into GPI− mice for a second round of transmission, to give GPI−/GPI [ME7] and GPI−/GPI [RML] mice. Disease signs in GPI− mice occurred later than in C57 mice; for example, RML caused terminal disease at >300 days after inoculation (dpi) in GPI−, and at about 142 dpi in C57 mice, similar to the values reported previously [63]. GPI− [RML] elicited disease in GPI− mice after 263 ± 47 dpi, suggesting adaptation of the RML prions to the novel environment.

Comparative quantitation of PrPSc by Western blotting and sandwich ELISA

We first analyzed the prion-infected brain samples for their content of PrPSc. Western blot analysis of C57[RML] and C57[ME7] brain homogenates showed three PrP-specific bands, attributed to d-, mono- and unglycosylated species, whose mobility increased after truncation by PK digestion (Figure 1A, lanes 1,2 and 9,10 respectively). The same amount or threefold higher of GPI [ME7] sample gave no detectable PrP signal (lanes 11–14), while GPI−/GPI [ME7] (lane 17) and GPI−/GPI [RML] (lane 5) samples gave rise to a ladder of bands with mobilities corresponding to about 28 to >250 kDa. Treatment with PK
converted the ladders to 2 bands (lanes 6, 8, 18), the major one corresponding to unglycosylated and the minor one to mono-
glycosylated GPI-PrP, as shown by the fact that PNGase digestion abrogates the slower-moving band (Figure 1B, lanes 2 and 12). The aggregated forms of GPI-PrP are likely derived from the abundant amyloid plaques described earlier [60]. Although GPI [ME7] brain homogenate from mice culled at 300 dpi showed barely a trace, if any at all, of PrP<sup>Sc</sup> on western blots (Figure 1A, lanes 12, 14) it nonetheless caused clinical disease by about 170 and 450 dpi when inoculated into wild-type and GPI<sup>-</sup> mice, respectively (Table S1, #20, 21), raising the suspicion that quantitation by western blot was erroneous. Nishina and Supattapone have reported that PrP<sup>Sc</sup> deprived of a GPI anchor by PIPLC-treatment was retained by the PVDF membranes used for western blotting at less than about 5% the efficiency of its GPI-linked counterpart [69]. We therefore compared the levels of PrP<sup>Sc</sup> in PK-treated samples from GPI<sup>-</sup> and C57 mice by western blotting and by sandwich ELISA, in which PK-treated, denatured samples were bound to wells coated with anti-PrP antibody D18 and visualized with biotinylated antibody D13. Astonishingly, sandwich ELISA revealed levels of PrP<sup>Sc</sup> in GPI<sup>[RML]</sup> and GPI<sup>/GPI<sup>[ME7]</sup></sup> brain 50- and 25-fold higher, respectively, than those in C57[RML] brain (Figure 1C) rather than 30% and >50% lower, as indicated by western blotting (Figure 1A).

Figure 1D shows that quantitation of PrP<sup>Sc</sup> by western blot and sandwich ELISA are consistent for wild-type brain but highly discordant for GPI<sup>-</sup> brain. Moreover, sandwich ELISA showed that the GPI [ME7] samples, which were negative by western blotting, in fact contained PrP<sup>Sc</sup> at about 12% the level in C57[ME7] brains. Brains from GPI<sup>-</sup> mice infected with 22L, 79A and 139A were not examined by western blotting or sandwich ELISA.

In summary, using the sandwich assay rather than western blotting for the quantitation of PrP<sup>Sc</sup>, it became evident that RML and ME7 prions propagating in GPI<sup>-</sup> mice gave rise to unusually high levels of PrP<sup>Sc</sup>, likely due to greater stability of extracellular as compared to intracellular PrP<sup>Sc</sup>.

Characterization of GPI<sup>-</sup> [RML] and C57[RML] prions by the CPA

Homogenates of prion-infected brains from GPI<sup>-</sup> and C57 mice were analyzed by the CPA. In this assay, the cell lines CAD, PK1, LD9 and R33<sub>3H11</sub> are infected with serial dilutions of a prion preparation and the proportion of infected cells is plotted against the logarithm of the dilution. The Response Index (RI) is defined as the dilution of the prion preparation at which an arbitrary proportion of cells (in this paper usually 3%) becomes PrP<sup>Sc</sup> positive. The ratio of RI's for a prion preparation on a set of cell lines is a characteristic strain property [2]. Additional valuable strain discrimination is provided by the glycosylation inhibitors swainsonine (swa), kifunesine (kifu) and castanospermine (csp), which inhibit chronic infection of PK1 cells by various strains to different extents [70]. Swa [70–72] and kifu [71] are potent and selective inhibitors of class II and class I α-mannosidases, respectively, and lead to replacement of complex N-glycans by high-mannose glycans. Csp [72], by inhibiting glucosidases, causes replacement of complex glycans mainly by glucose-containing, high-mannose oligosaccharides.

As shown by the CPA in Figure 2A, RML prions from C57 brain were swa sensitive on PK1 cells and R33<sub>3H11</sub> incompetent, i.e. unable to infect R33<sub>3H11</sub> cells efficiently, while RML-derived prions from GPI<sup>-</sup> brain were swa resistant and R33<sub>3H11</sub> competent; moreover, the RI<sub>CAD/RI_PK1</sub> ratio was lower for the C57-derived than for the GPI<sup>-</sup> derived samples. The bar diagram (Figure 2B) shows log[RI<sub>CAD/RI_PK1</sub>] (blue) and log[RI<sub>PK1/RI_3H11swa</sub>] (red) values plotted for 22L, RML, 79A, and 139A, propagated in C57 or GPI<sup>-</sup> brain. The quantified data clearly show that C57[RML] and GPI<sup>[RML]</sup> give vastly different patterns, as do their 79A and 139A counterparts. The statistical significance of the “log(ratio)” differences between two strains is given in the matrix of Figure 2C. For example, the difference between C57[RML] and GPI<sup>[RML]</sup> is highly significant for both ratios, whereas there is no significant difference between C57[22L] and GPI<sup>[22L]</sup> by the criteria used here. Interestingly, the differences between C57[RML] and C57[139A] are significant for both ratios, but not those between C57[RML] and C57[79A], contradicting the common assumption that RML and 139A are the same strains [67] and confirming the cognate conclusions of Browning et al. [73] and Oelschlegel et al. (personal communication).

From the RI values shown in the Figures and the PrP<sup>Sc</sup> content relative to RML (Figure 1D) the relative specific infectivities (RI/PrP<sup>Sc</sup>) of RML and ME7 prions (second passage) derived from GPI<sup>-</sup> mice were calculated and found to be 6- and 25-fold lower, respectively, than those from C57 mice (Table 1), suggesting that PrP<sup>Sc</sup> accumulating extracellularly was either inherently less infectious or lost infectivity over time.

Transfer of GPI<sup>-</sup> [RML] prions to C57BL/6 mice

Because PrP<sup>Ec</sup> and PrP<sup>Sc</sup> in GPI<sup>-</sup> mice lack the GPI anchor and are also largely unglycosylated (Figure 1B) [1], the question arose whether the differences in the CPA characteristics of GPI<sup>-</sup>-derived and wild-type prions were due to these structural features (which we considered unlikely because GPI-linked PrP<sup>Sc</sup> arises immediately after infecting the cells for the CPA) or to a conformational change of the PrP<sup>Sc</sup>. We therefore inoculated brain homogenate from GPI<sup>-</sup> [RML] mice into C57BL/6 mice to generate C57/GPI<sup>-</sup> [RML] prions, whose PrP<sup>Sc</sup> then carried a GPI anchor and was normally glycosylated (Figure 1B, lanes 5). The resulting brain homogenate was serially transmitted twice more to C57BL/6 mice, to yield C57/C57/GPI<sup>-</sup> [RML] (Figure 1B, lanes 7, 8) and C57/C57/C57/GPI<sup>-</sup> [RML] prions (Figure 1B, lanes 9, 10; Figure 1A, lanes 3, 4).

C57BL/6 mice inoculated with prions from GPI<sup>-</sup> [RML] brain exhibited pronounced clinical signs of RML scrapie disease after 150±9 days, similar to those of mice inoculated with the original C57/RML (Table S1, #4a-1b; #1). However, as shown in Figure 3A, C57/GPI<sup>-</sup> [RML] prions neither retained the drug susceptibility pattern of GPI<sup>-</sup> [RML], nor did they regain the characteristic pattern for the original C57/RML prions, even after two additional transfers through C57 mice. From the bar diagram (Figure 3B) it can be seen that the log[RI<sub>PK1/RI_3H11swa</sub>] (red) values for C57/GPI<sup>-</sup> [RML] and C57/C57/GPI<sup>-</sup> [RML] prions, 0.6, 0.7, and 0.7, 0.8, respectively, were indistinguishable, but far lower than those for C57/RML prions, 2.8 and 1.4, respectively. The statistical evaluation shown in the matrix of Figure 3C confirms the significance of these conclusions.

In a further experiment (Figure 3D), the susceptibility of prion replication in PK1 cells to inhibition by csp and, again, kifu was tested. The bar diagram (Figure 3E, blue bars) shows that kifu, as before, inhibited infection of PK1 cells by RML by more than 3 logs but had little effect on infection by C57/GPI<sup>-</sup> [RML] or C57/C57/GPI<sup>-</sup> [RML] prions, and Figure 3F documents the statistical significance of the conclusions. In addition, we cloned RML prions in PK1 cells, propagated them in mouse brain and determined that none of twelve RML subclones exhibited kifu resistance, excluding the possibility that SFL was a significant
Csp inhibited RML infection of PK1 cells by about 2 logs, but that of GPI
2-derived prions passed once or twice in C57 mice by only about 1 log (Figure 3E, green bars). Thus, as judged by the CPA and by inhibitor susceptibility, RML prions passed through GPI
2 brain acquired novel characteristics and these were retained even after three serial passages through C57BL/6 brain.

The conformational stability assay [26] showed no difference between the PrP\textsuperscript{res} associated with wild-type RML, C57/GPI
2[RML] and C57/C57/GPI
2[RML], however GPI
2[RML] PrP\textsuperscript{res} seemed slightly more stable; whether this reflects a conformational difference or a difference due to the absence of GPI anchor and paucity of N-glycans remains unknown (Figure S2).
Figure 2. The cell tropism of various prion strains changes after propagation in tgGPI^2 mice. Homogenates of GPI^2 or C57 brains infected with the strains indicated were subjected to the CPA. (A) The patterns elicited by 22L from both sources were very similar, however RML, 79A and 139A prions from wild-type brain were swa sensitive on PK1 cells and R33^T111 incompetent, while those from tgGPI^2 brain were swa resistant.
Characterization of GPI- [ME7] and C57[ME7] prions by the CPA

Typical scrapie signs were not observed in ME7-inoculated GPI- mice by 300–305 days, at which time mice showing mild clinical signs were euthanized and homogenates of their brains were subjected to the CPA. The level of infectivity of GPI- [ME7] brain homogenates as measured on CAD and PK1 cells was very low (RI<10^5), however LD9 cells showed a higher response (RI = 1.1 × 10^6), albeit at a level about 25 times lower than that found for C57[ME7] brains (2.8 × 10^6) (Figure 4). The GPI- [ME7] brain homogenates were infectious to wild-type mice, leading to disease at 170±0 dpi (Table S1, #20), as compared to 135±4 days for “normal” C57[ME7] (Table S1, #18b), and yielded prions indistinguishable from the original ME7, as judged by the CPA. A second transmission of GPI- [ME7] prions to GPI- mice resulted in disease at 447±64 dpi (Table S1, #21) and, interestingly, to high levels of PrPres, as determined by sandwich ELISA (Figure 1C, 1D), and infectivity, as measured on CAD cells (RI = 1.5×10^6; Figure 4A). GPI-/GPI- [ME7] prions differed from C57[ME7] prions by their log[RI_{LD9}/RI_{CAD}] value, -0.03 versus 0.7; whether or not they revert to the original ME7 after being returned to C57 is still under investigation (Table S1, 22.)

In summary, repeated propagation of ME7 prions through GPI- brain resulted in a distinct alteration of their properties, reflecting progressive adaptation to the modified environment. However, prions returned from GPI- [ME7] mice to C57 mice resulted in reversion to prions indistinguishable from the original C57[ME7] prions.

Discussion

Prion populations are considered to be “quasi-species”, i.e. to consist of a major component and a multiplicity of variants present at low levels, of which one may be selected as the major component if the population is exposed to a different environment [39,74,75].

We have reported previously that when 22L prions were transferred from brain to PK1 or R33 cells, their properties, as measured by the CPA, changed gradually in the course of many doublings, suggesting that a 22L variant present at low levels in the brain-derived population was being selected in the cellular environment. Conversely, when the cell-adapted 22L variants were again propagated in brain, the resulting population gradually re-acquired the properties of the original brain-derived 22L. When 22L prions were cloned by endpoint dilution into PK1 cells they were initially swa sensitive and incapable of developing swa resistance (“swa incompetent”), but as the populations were further propagated they became swa competent while remaining swa sensitive, suggesting that during propagation swa-resistant prions arose at a low level by “mutation” and could be selected when the population was challenged with swa [74–76].

In all these cases the changes were reversed when the prions were propagated in the original environment; assuming that properties of prions are encoded by the precise conformation of the cognate PrPSc, we concluded that the conformational states underlying adaptation to the cellular environment are separated by low activation energy barriers which allowed reversible conformational switches leading to “strain variants” or “sub-
Figure 3. RML prions propagated in tgGPI<sup>2</sup> mice and returned to wild-type mice emerge as a novel, stable strain. Analysis of authentic RML prions propagated in C57BL/6 brain (C57[RML]), and of RML prions first propagated in GPI<sup>−</sup> brain (GPI<sup>−</sup>[RML]) and then once (C57/GPI<sup>−</sup>[RML]), twice (C57/C57/GPI<sup>−</sup>[RML]) or three times (C57/C57/C57/GPI<sup>−</sup>[RML]) in C57BL/6 brain. (A) shows the SSCA performed on PK1 cells in the presence or absence of kifunensine (kifu; 5 µg/ml) or swainsonine (swa; 2 µg/ml) for the samples indicated; C57[22L] was added as control. RI’s were determined at 600 spots (RI<sub>600</sub>). Kifu strongly inhibited the propagation of C57[RML], but not of C57/GPI<sup>−</sup>[RML] and C57/C57/C57/GPI<sup>−</sup>[RML] prions on PK1 cells. (B) The bar graph shows the log[R<sub>PK1</sub>/R<sub>PK1</sub> <sup>+</sup> kifu] and log[R<sub>PK1</sub>/R<sub>PK1</sub> <sup>+</sup> swa] values for the samples listed in (A). The pairwise comparison in panel (C) shows that C57/GPI<sup>−</sup>[RML] and C57/C57/C57/GPI<sup>−</sup>[RML] prions do not differ significantly, but are vastly different from C57[RML] and GPI<sup>−</sup>[RML] prions. The framed “ns” indicates high p values (>0.1) for both log[ratios], indicating no significant difference between the samples. (D) Effect of castanospermine (csp; 50 µg/ml) or kifu (5 µg/ml) on propagation of the samples indicated on PK1 cells. As in (A), kifu strongly inhibits the propagation of C57[RML], but not C57/GPI<sup>−</sup>[RML] and C57/C57/GPI<sup>−</sup>[RML] prions. The same is true for csp, however to a lesser extent. (E) The bar graph depicts the log[R<sub>PK1</sub>/R<sub>PK1</sub> <sup>+</sup> kifu] (blue) and log[R<sub>PK1</sub>/R<sub>PK1</sub> <sup>+</sup> csp] (green) values. The R<sub>PK1</sub>/R<sub>PK1</sub> <sup>+</sup> kifu ratio was >500-fold lower for C57/GPI<sup>−</sup>[RML]
and C57/C57/GPI [RML] than for C57/RML prions, again underscoring the difference between RML prions and the novel strain. The matrix (F) also shows that C57/GPI [RML] and C57/C57/GPI [RML] prions do not differ from each other, but that both differ significantly from C57/RML prions. In summary, the figure sustains the conclusion that a new strain, designated SFL, emerged after RML prions were passaged through GPI brain and returned C57 brain, and that they remained unchanged after two further passages.

doi:10.1371/journal.ppat.1002746.g003

Prion preparations

The 22L strain, cloned by two successive end-point dilutions, as well as strains 79A and 139A were obtained from the TSE Resource Centre, Compton, Newbury, UK (I. McConnell, R.M. Barron). The RML strain, from the MRC Prion Unit, University College, London, was propagated initially in CD1 mice and subsequently in C57BL/6 mice.

Brains were harvested from mice exhibiting neurological signs of prion diseases in C57BL/6. In some cases where inoculated, anchorless mice showed only mild clinical signs, brains were taken at 300 days post inoculation. For stock homogenates, frozen brains were pooled and homogenized for 10 sec in PBS (9 ml per g) using a hand-held Ultramax T18 basic homogenizer (IKA Works Inc., Bloomington, NC) at 20000–25000 rpm. Single frozen brains were homogenized in PBS using a ribolysin (FastPrep FP120, Bio 101, Thermo Electron Corp., Thermo Fischer Scientific, MA) with ZrO 0.8–1 mm beads (cat. No. 7305-000010, Glen Mills Inc., Clifton, NJ), at maximum speed 6.5 for 15 seconds in Fast Prep tubes (MP Biomedicals).

Cell culture

The cell lines PK1 and R32c111, are derived from N2a neuroblastoma cells, CAD5 (CAD) from Cath.a-differentiated cells, and LD9 from L299 fibroblasts [33,82]. The lines were maintained in OBGS (Opti-MEM [Invitrogen], 4.5% Bovine Growth Serum [Hyclone, Logan, UT], 90 units penicillin/ml, 90 µg streptomycin/ml [Invitrogen]). Cells were split 1:10, or 1:6 if sparse, twice a week. After 9 serial passages cells were replaced with freshly thawed samples.

The Standard Scrapie Cells Assay (SSCA)

The SSCA was performed as detailed earlier [82]. In summary, serial 1:3 dilutions of the sample (300 µl) were placed in quadruplicate wells in 96-well plates with 5000 susceptible cells per well. Four days after infection the confluent monolayer was suspended and split 1:7 in OBGS for total 3 splits, allowing cells 3–4 days to form a confluent layer between each split. After the third split, cells were grown to confluence again, 20000 cells were added to the wells of pre-activated Multiscreen IP96-well 0.45-µm Immobilon P membrane plates (Millipore, Danvers, MA) and vacuumed onto the membrane. After baking at 50°C for 1 h, samples were treated with 1 µg proteinase K (PK, Roche)/ml in lysis buffer, followed by PMSF and denaturation with guanidinium thiocyanate. In more recent assays the PMSF step was omitted. After washing with PBS, wells were blocked with 0.5% milk in 1× TBS and incubated with humanized anti-PrP antibody D18 [83] followed by mouse anti-human IgG7 AP-conjugated antibody in 0.5% milk-TBST. Signals were visualized with AP Conjugate Substrate Kit (BioRad) and PHEOS-positive cells (“spots”) were counted using the Bioreader 5000-Eb (BioSys). To control for residual inoculum, the prion replication inhibitor pentosan polysulfate (PPS) was added during the 4-day infection at 10 µg/ml to the cells infected with the highest concentration of prion sample.

Materials and Methods

Ethics statement

When working with mice all efforts were made to minimize suffering. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institute of Health. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC). Scripps Florida has an Animal Welfare Assurance on file with the Office of Laboratory Animal Welfare (OLAW), National Institute of Health (assurance number #A4460-01). Scripps Florida’s registration under USDA regulations is certificate 93-R0015. The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) awarded Scripps Florida full accreditation.

Mouse inoculations

C57BL/6 mice were from Charles River Laboratories (Wilmington, MA). Breeding pairs of tgGPT mice [60] were obtained from the Oldstone laboratory. Mice were anesthetized with isoflurane and 30-µl samples of 1% brain homogenates were inoculated in the prefrontal cortex. When pronounced clinical signs became evident, or earlier, the mice were asphyxiated with CO2 and subjected to cervical dislocation.

Prions are conformational states which we designated SFL, distinct from that of the original RML, was stably maintained. Because SFL does not revert to RML, it must be either better adapted to propagation in the original host. Mutated PrPSc could be formed if accretion of G P1−PrPSc to wild-type seed entailed adoption of a conformation slightly different from that of the seed, or if wild-type PrPSc contained a variety of mutant seeds—possibly at a low level—to one or some of which the resident G P1−PrPSc preferentially accreted, adopting its conformation [76].

Considering the large variety of “classical” murine prion strains [79], the plethora of strains generated by Prusiner and his colleagues [80,81] and the many variants we have observed, all encoded by a single murine PrP sequence, the number of stable conformational states must be vast. The structural elucidation of PrPSc and its variants continues to be the Holy Grail of the prion field.

Prions are conformational states which we designated SFL, distinct from that of the original RML, was stably maintained. Because SFL does not revert to RML, it must be either better adapted to propagation in the original host. Mutated PrPSc could be formed if accretion of G P1−PrPSc to wild-type seed entailed adoption of a conformation slightly different from that of the seed, or if wild-type PrPSc contained a variety of mutant seeds—possibly at a low level—to one or some of which the resident G P1−PrPSc preferentially accreted, adopting its conformation [76].

Materials and Methods

Ethics statement

When working with mice all efforts were made to minimize suffering. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institute of Health. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC). Scripps Florida has an Animal Welfare Assurance on file with the Office of Laboratory Animal Welfare (OLAW), National Institute of Health (assurance number #A4460-01). Scripps Florida’s registration under USDA regulations is certificate 93-R0015. The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) awarded Scripps Florida full accreditation.

Mouse inoculations

C57BL/6 mice were from Charles River Laboratories (Wilmington, MA). Breeding pairs of tgGPT mice [60] were obtained from the Oldstone laboratory. Mice were anesthetized with isoflurane and 30-µl samples of 1% brain homogenates were inoculated in the prefrontal cortex. When pronounced clinical signs became evident, or earlier, the mice were asphyxiated with CO2 and subjected to cervical dislocation.
The number of PrPres-positive cells is plotted as a function of the logarithm of the dilution. The “Response Index” (RI) of a sample is the reciprocal of the concentration that gives rise to a designated proportion of PrPSc-positive cells under standard assay conditions (in our experiments, RI at 600 positive cells per 20,000 cells, or 3%).

Cell Panel Assay

The Cell Panel Assay (CPA) allows the characterization of strains by virtue of their cell tropism and their susceptibility to inhibitors, as determined by the SSCA performed on CAD5, PK1, LD9 and R332H11 cells. A strain or a substrain is characterized by the ratio of RIs on different cell lines and by the susceptibility to

Figure 4. ME7 prions propagated in tgGPI- mice for one or two passages acquire novel characteristics. (A) Serially diluted brain homogenates were analyzed on LD9, CAD and PK1 cells by the CPA. After the first passage of ME7 prions in GPI- mice (GPI-[ME7]), the RI on CAD cells dropped 20-fold, most likely reflecting low titers, but increased about 30-fold after the second passage (GPI+/GPI-[ME7]), indicating adaptation to the GPI- environment. Returning prions from the first passage in GPI- brain to wild-type brain (C57/GPI-[ME7]) restored the original CPA pattern. (B) Log(RI_LD9/RI_CAD) (red) and log(RI_LD9/RI_PK1) (blue) are plotted as a bar graph. (C) The matrix shows that C57/[ME7] and C57/GPI-[ME7] prions do not differ, while both differ in at least one log(ratio) from GPI-[ME7] and GPI+/GPI-[ME7] prions.

doi:10.1371/journal.ppat.1002746.g004
inhibition by drugs. When required, glycosylation inhibitors swainsonine (swa, Logan Natural Products; 2 μg/ml), kilunisine (kiu, Toronto Research Chemicals Inc.; 5 μg/ml) and castanospermine (csp, Toronto Research Chemicals Inc.; 50 μg/ml) were present during infection and up to the second split, and were diluted thereafter with each split.

End-point dilution cloning of RML in cell culture
PK1 cells were seeded at 100 cells/well in 96-well plates and inoculated with highly diluted RML-infected brain homogenates (final concentration: 10⁻¹⁰; 5×10⁻¹⁰⁻⁶). The cells were repeatedly grown to confluence and subjected to three 1:10 splits, followed by eight 1:10 splits; after a total of about 30 doublings 20000 cells from each well were subjected to the PK-Elispot Assay and samples containing PrP⁺⁺⁺⁺-positive cells (spot numbers>background+5 SDs) were scored as positive. The proportion of positive wells was 27/168 (16%) for an inoculum dilution of 10⁻⁹ and 27/252 (11%) for an inoculum dilution of 5×10⁻¹⁰⁻⁹. The probability \( P_{X=1} = 1 - e^{-m} \) that under the conditions chosen a well was infected by more than one prion was 10⁻²–10⁻³ or less, where \( m \) is the average number of prions/well. Nine prion clones were expanded, conditioned media was harvested, concentrated and inoculated into C57BL/6 mice. The brain homogenates from terminally ill mice were characterized by the SSCA on PK1 cells in the presence or absence of 5 μg BSA/ml for all 9 clones from the 1st round of cloning. In addition, prions from several RML-infected PK1 (PK1[RML]) clones were expanded, conditioned media was harvested, concentrated and inoculated into C57BL/6 mice. The brain homogenates from terminally ill mice were characterized by the SSCA on PK1 cells in the presence or absence of 5 μg BSA/ml.

Western blot analysis
Samples were denatured by boiling in 15 mM Tris-HCl (pH 8.0) with the volumes were equalized to 0.2 M GndCl concentration in each sample was then adjusted to 0.2 M Triton X-100 and digested with 0.6 μg/ml PK (PK : protein = 1:50 by weight) in 10 mM Tris-HCl (pH 8.0). Samples were adjusted to 0.5% Triton X-100 and digested with 0.6 μg/ml PK (PK : protein = 1:50 by weight) with shaking at 1000 rpm for 1 h at 37°C in an Eppendorf thermomixer; digestion was terminated by addition of PMSF to 2 mM. After addition of 5 μg BSA, proteins were precipitated with TCA (10% final concentration), chilled on ice for 30 min, and centrifuged 15 min at 16000× g and 4°C. Pellets were resuspended in 0.5 ml cold acetone, re-centrifuged and resuspended in 50 μl PBS-0.5% Triton X-100. Samples were heated 10 min at 100°C in MES sample loading buffer (Bio-RAD) and analyzed by western blotting. Chemiluminescence was induced by ECL-Plus (Pierce), recorded and quantified by CCD imaging (BioSpectrum AC Imaging System; UVP). The highest value of each curve was set to 100% and the Gnd₁/₂ value, i.e. the GndCl concentration at which 50% of the PrP⁺⁺⁺⁺ was digested by PK under standard conditions, was determined.

Sandwich ELISA
The procedure is essentially as described earlier [17]. Ninety-six-well plates (F16 Maxisorp Nunc Immune Module, Nunc) were rocked overnight with 15 μg/ml D18 antibody/well at 4°C, washed with PBST 3 times, blocked with 5% milk in PBST at 37°C for 1 h, washed again in PBST 3 times and stored with 200 μl PBS per well at 4°C. Brain homogenates were diluted to 3 mg total protein/ml in 0.5% Triton X-100. Samples with high PrP⁺⁺⁺⁺ content were diluted appropriately with PrP⁺⁺⁺⁺ brain homogenate to give a final protein concentration of 3 mg/ml. Samples were shaken with 12.5 μg protease K (PK) in PBST at 37°C for 1 h, and adjusted to 6 mM PMSF, giving a protein concentration of 2.8 mg/ml. A 7.2-μl aliquot of each sample was denatured with an equal volume 8 M GndCl (Research Products International Corp.) for 5 min at 80°C and diluted in Sandwich Assay Buffer (50 mM Tris-HCl, pH 8.0, 2% Triton X-100, 2% sodium lauroylsarcosine, 2% BSA) to a final volume of 1 ml. Quadruplicate 300-μl sample aliquots were added to the wells of blank 96-well tissue culture plate (BD Falcon) and serially diluted 1:2 in Sandwich Assay Buffer. When used as a standard, recombinant PrP (200 ng/ml in 2.8 mg/ml PrP⁺⁺⁺⁺ brain homogenate) was serially diluted into 2.8 mg/ml PrP⁺⁺⁺⁺ brain homog-

Figure 5. Conjectural free energy profile. (A) The RML quasi-species in wild-type brain are confined to a set of wells separated from those of the SFL quasi-species by a high activation energy barrier. (B) In tgGPI- brain the transition to the “SFLGPI⁺⁺⁺⁺” set of conformations is enabled by a lower activation energy barrier. (C) SFLGPI⁺⁺⁺⁺ prions introduced into wild-type brain can now occupy, and are trapped in, the set of “SFL wells” which was not accessible to RML prions in (A). doi:10.1371/journal.ppat.1002746.g005
enate. A 150-μl aliquot of each sample was transferred to the D18-coated wells and rocked 1 h at 37°C. Plates were washed 5 times with PBST (0.1% Tween/PBS) and to each well was added 100 μl biotinylated D13 antibody [83] at 1.3 μg/ml 1% milk-PBST. After rocking for 1 h at 37°C in 1% milk-PBST, plates were washed 5 times with PBST and to each well was added 100 μl 1:75000 HRP-streptavidin (Amersham GE Healthcare) in 0.5% BSA-PBST for 30 min at 37°C. After 5 washes with PBST, 100 μl TMB Super-sensitive HRP microwell substrate (SUB2) was added, and after 2 min at room temperature the reaction was stopped with 100 μl TMB Microwell Stop solution (STOP1; Immunochemistry Technologies, MN). Plates were read with a BioTek 450 plate reader (BioTek Instruments, VT) and analyzed with Gen5 software.

Supporting Information

Figure S1 Determination of kifunensin-susceptibility of twelve independent clones of RML. PK1 cells were infected with a high dilution of RML prions as described in the Methods section. Prions from RML-infected clones were inoculated in C57BL/6 mice and serial dilutions of homogenized brains were analyzed by the SSCA on PK1 cells in the presence or absence of 5 μg kifu/ml. All 12 clones were indistinguishable from the original RML in being strongly inhibited by kifu. RML and the clones were distinctly different from SFL, which was only weakly inhibited by kifu. The SSCA of only one representative of the 12 clones (#3) is shown.

Figure S2 Sandwich ELISA of samples from Figure 1A. Absorbance of quadruplicate samples is plotted against input protein on a linear plot, to show that absorbance is almost linear with input protein up to 1.5 μg/well. NBH, uninfected C57 brain homogenate.

Figure S3 Conformational stability of PrP⁰⁰⁰ from various strains. The assay was described in the Methods section. The highest value for each curve was set to 100% and the concentration of GndCl at which 50% of the PrP was digested by PK is represented by the dotted lines. PrP⁰⁰⁰ from RML (lilac), C57/GPI [RML] (green) and C57/C57/GPI [RML] (blue) showed no significant differences in stabilities, which ranged from 1.7 to 1.9 M GndCl. GPI⁻ [RML] (red) had a marginally higher stability (2.2 M GndCl).

Figure S4 Kinetic Protein Misfolding Cyclic Amplification (PMCA). PMCA was performed to identify differences in rate constants of amplification of PrP⁰⁰⁰ from C57[RML] and C57/GPI [RML] brains. PMCA substrate (uninfected C57 brain homogenate) was prepared as described [84], but without centrifugation. Prion “seeds”, RML and SFL (C57/GPI [RML]) PrP⁰⁰⁰ were adjusted to the same levels, as determined by densitometric analysis on western blots. (A) PMCA reaction mixtures contained 441 μl substrate and either 9 μl of a 10⁻² dilution of RML or an equivalent amount of SFL PrP⁰⁰⁰. PMCA was performed with 60-μl aliquots of the reaction mixtures dispensed in triplicate into 200-μl PCR tubes (Axygen) containing 37 ± 3 mg of 1.0 mm Zirconia/Silica beads (BioSpec products). Samples were subjected to cycles of 20 second sonication and 30 min incubation at 37°C for 0, 0.6, 0.9, 1.5, 2.2, 3.3 or 5 h, using a Misonix 3000 sonicator at power setting 8.3. To measure amplified PrP⁰⁰⁰, 20-μl aliquots were PK-digested and 10 μl were electrophoresed and analyzed as previously described [73]. (B) Western blots were quantified and the ratio rPrP⁰⁰⁰/time 0/ rPrP⁰⁰⁰(time 0) was plotted on a log scale against time. The rate constants were calculated from the logarithmic phases of the kinetics (up to 3.3 h). (C) There were no statistically significant differences (t student) in the rate constants of RML and C57/GPI [RML] PrP⁰⁰⁰ amplification.

Table S1 Incubation periods and clinical signs for C57BL/6 and tgGPI- mice inoculated with various inocula.

Acknowledgments

We thank C.A.Demczyk for assistance with cell culture, M.Fallahi for advice on statistical evaluation, M.Zhou for recombinant PrP from E.coli, E.Smith Jr. and J.Treadaway for assistance with the SSCA, and A.Sherman and S.Oritz-Umpierre (SO) for carrying out the mouse experiments.

Author Contributions

Conceived and designed the experiments: SPM CW. Performed the experiments: SPM JJ ISK MEH AMO. Contributed reagents/materials/analysis tools: MO. Experiments: SPM JJ ISK MEH AMO SPM CW. Analyzed the data: JJ ISK MEH AMO SPM CW. Wrote the paper: SPM CW.

References

1. Endo T, Groth D, Prusiner SB, Kobata A (1989) Diversity of oligosaccharide structures linked to asparagines of the scrapie prion protein. Biochemistry 28: 8380–8388.
2. Rudd PM, Endo T, Colominas C, Groth D, Wheeler SF, et al. (1999) Diversity of oligosaccharide isoforms. Proc Natl Acad Sci U S A 96: 13044–13049.
3. Rudd PM, Wormald MR, Wing DR, Prusiner SB, Dwek RA (2001) Prion glycosylation of PrPSc. J Gen Virol 86: 241–246.
4. Hegde RS, Mastrianni JA, Scott MB, DeFea KA, Tremblay P, et al. (1998) A novel strategy for the development of a cellular prion protein expression system. J Biol Chem 273: 279: 827–834.
5. Somervelle RA, Hamilton S, Fernie K (2005) Transmissible spongiform encephalopathy strain, PrP genotype and brain region all affect the degree of glycosylation of PrPC. J Gen Virol 86: 241–246.
6. Monnet C, Mathiessen V, Enden H, Frobert Y, Sobel A, et al. (2003) Heterogeneity and regulation of cellular prion protein glycoforms in neuronal cell lines. Eur J Neurosci 18: 542–548.
7. Borchtet DR, Rogers M, Stahl N, Telling G, Prusiner SB (1993) Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor. Glycobiology 3: 319–329.
8. Hegde RS, Mastrianni JA, Scott MB, DeFea KA, Tremblay P, et al. (1998) A transmembrane form of the prion protein in neurodegenerative disease. Science 279: 827–834.
9. Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB, et al. (1999) Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402: 822–826.
10. Goold R, Rabbanian S, Sutton L, Andre R, Arora P, et al. (2011) Rapid cellular surface prion protein conversion revealed using a novel cell system. Nat Commun 2: 281.
11. Campa V, Sarnataro D, Zurrizzo C (2005) The highways and byways of prion protein trafficking. Trends Cell Biol 15: 102–111.
12. Veith NM, Plattner H, Stuermer CA, Schulz-Schaeffer WJ, Burke A (2009) Immunolocalisation of PrPSc in scrapie-infected N2a mouse neuroblastoma cells by light and electron microscopy. Eur J Cell Biol 88: 45–63.
39. Collinge J, Clarke AR (2007) A general model of prion strains and their propagation. Nature 42: 229–235.
40. Weissmann C (2004) The state of the prion. Nat Rev Microbiol 2: 861–871.
41. Jarrett JT, Lansbury PJ (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1223–1238.
42. Wang F, Wang X, Yuan CG, Ma J (2010) Generating a prion with bacterially expressed recombinant prion protein. Science 327: 1132–1135.
43. Nandi PK (1998) Polymerization of human prion peptide HuPrP 106–126 to amyloid in nucleic acid solution. Arch Virol 143: 1251–1263.
44. Gabus C, Derrington E, Loh E, Chaubadaier J, Dormont D, et al. (2001) The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCP7 of HIV-1. J Biol Chem 276: 19721–19727.
45. Gomes MP, Mullen TA, Ferrerias P, Serra ML, Viera TC, et al. (2008) Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells. J Biol Chem 283: 19616–19625.
46. Nandi PK (2000) Combinatorial changes of prion protein and nucleic acid arising from their interaction and relation of the altered structures in causing prion diseases. Mini Rev Med Chem 2: 175–180.
47. Daleuvt NR, Lacassen RW, Suppatpon C (2003) RNA molecules stimulate prion protein conversion. Nature 425: 717–720.
48. Daleuvt NR, Harris BT, Rees JR, Suppatpon S (2007) Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A 104: 12070–12075.
49. Wang F, Zhang Z, Wang L, Zha L, et al. (2011) Genetic informational RNA is not required for recombinant prion infectivity. J Virol 16: 16.
50. Kuczum T, Koch R, Keyeynn K, Karch H, Grass J, et al. (2007) Regional and phenotype heterogeneity of cellular prion proteins in the human brain. Eur J Neurosci 25: 2649–2655.
51. DeArmond SJ, Sanchez H, Yelisey F, Qin Y, Ninikha-Casey A, et al. (1997) Selective neuronal targeting in prion disease. Neuron 19: 1337–1348.
52. Telling GC, Scott M, Massari R, Gabizon R, Torchia M, et al. (1995) Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 73: 79–90.
53. Nishina KA, Daleuvt NR, Mahal SP, Baskakov I, Luhrs T, et al. (2006) The stoichiometry of host PrP complexed with PrP aggregates modulates the efficiency of PrPSc formation in vitro. Biochemistry 45: 11429–11439.
54. Salamat MK, Dren M, Chauvin J, Langevin C, Laude H (2011) Prion propagation in cells expressing PrP glycosylation mutants. J Virol 85: 7057–7065.
55. Cappelletti E, Bradford RM, Tusi NL, Hickey RD, Brown D, et al. (2010) Glycosylation of PrPC determines timing of neuroinvasion and targeting in the brain following transmissible spongiform encephalopathy infection by a peripheral route. J Virol 84: 4546–4547.
56. Neuenschwander E, Weber A, Schafft H, Reifenberg K, et al. (2004) Glycosylation deficiency at either one of the two glycan attachment sites of cellular prion protein preserves susceptibility to bovine spongiform encephalopathy and scrapie infections. J Biol Chem 279: 53506–53516.
57. Auger RC, Kang HE, Napier D, Browning S, Seward T, et al. (2010) Prion strain mutation determined by prion protein conformational compatibility and primary structure. Science 328: 1134–1138.
58. Chesebro B, Trifillo M, Race R, Meade-White K, Teng C, et al. (2005) Anchored prion protein results in infectious amyloid disease without clinical scrapie. Science 308: 1435–1439.
59. McNally KL, Ward AE, Priola SA (2009) Cells expressing anchorless prion protein are resistant to scrapie infection. J Virol 83: 4469–4475.
60. Lee AM, Paulsson JF, Crane J, Andaya AA, Trifilo MJ, et al. (2011) Extraneural manifestations of prion infection in GPI-anchorless transgenic mice. Virology 411: 1–8.
61. Chesebro B, Race B, Meade-White K, Lacosse R, Race R, et al. (2010) Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with loss of prion protein membrane anchoring. PLoS Pathog 6: e1000800.
62. Campana V, Caputo A, Sarnatolu D, Paladino S, Tovsard E, et al. (2007) Characterization of the properties and trafficking of an anchorless form of the prion protein. J Biol Chem 282: 22747–22756.
63. Priola SA, McNally KL (2009) The role of the prion protein membrane anchor in prion infection. Prion 3: 134–138.
64. Dickinson AG (1976) Scrapie in sheep and goats. Nature 254: 196–207.
65. Guscóp M, Greitzchel A, Kuczus T (2006) Prion strains. In: Hornblum B, Riesner D, Kretschmar H, eds. Prions in humans and animals. Berlin, New York: de Gruyter. pp 166–182.
66. Bruce ME, McConnell I, Fraser H, Dickson KA, de Gruyter C, et al. (1991) The disease characteristics of different strains of scrapie in Sinc congenic mouse lines: implications for the nature of the agent and host control of pathogenesis. J Gen Virol 72: 595–603.
67. Nishina KA, Suppatpon C (2007) Immunodetection of glycosphatidylinositol-anchorated proteins following treatment with phospholipase C. Anal Biochem 363: 318–320.
68. Tulsiani DR, Harris TM, Touster O (1982) Scrapie in sheep and goats. In: Prusiner SB, Collinge J, Powell J, Anderton B, eds. Prion Diseases of Humans and Animals. New York, London: Ellis Horwood. pp 307–322.
73. Browning S, Baker CA, Smith E, Mahal SP, Herva ME, et al. (2011) Abrogation of complex glycosylation by swainsonine results in strain- and cell-specific inhibition of prion replication. J Biol Chem 286: 40962–40973.
74. Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C (2010) Darwinian evolution of prions in cell culture. Science 327: 869–872.
75. Weissmann C, Li J, Mahal SP, Browning S (2011) Prions on the move. EMBO Rep 12: 1109–1117.
76. Li J, Mahal SP, Demczyk CA, Weissmann C (2011) Mutability of prions. EMBO Rep 14: 191.
77. Oelschlegel AM, Fallahi M, Ortiz-Umpierre S, Weissmann C (2012) The Extended Cell Panel Assay (ECPA) characterizes the relationship of RML, 79A and 139A prion strains and reveals conversion of 139A to 79A-like prions in cell culture. J Virol 29: 29.
78. Kimberlin RH, Cole S, Walker CA (1987) Temporary and permanent modifications to a single strain of mouse scrapie on transmission to rats and hamsters. J Gen Virol 68: 1873–1881.
79. Bruce ME (2003) TSE strain variation. Br Med Bull 66: 99–108.
80. Legname G, Nguyen HO, Peretz D, Cohen FE, DeArmond SJ, et al. (2006) Continuum of prion protein structures enciphers a multitude of prion isolate-specific phenotypes. Proc Natl Acad Sci U S A 103: 19105–19110.
81. Colby DW, Prusiner SB (2011) De novo generation of prion strains. Nat Rev Microbiol 9: 771–777.
82. Mahal SP, Browning S, Li J, Suponitsky-Kroyter I, Weissmann C (2010) Transfer of a prion strain to different hosts leads to emergence of strain variants. Proc Natl Acad Sci U S A 107: 22653–22658.
83. Williamson RA, Peretz D, Pinilla C, Ball H, Bastidas RR, et al. (1998) Mapping the prion protein using recombinant antibodies. J Virol 72: 9413–9418.
84. Saa P, Castilla J, Soto C (2005) Cyclic amplification of protein misfolding and aggregation. Methods Mol Biol 299: 53–65.